Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done

An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...

CRSP Stock: The First CRISPR Gene-Editing Drug Could Be Here Sooner Than You Think

Crispr Therapeutics (CRSP) said Tuesday it will begin asking the Food and Drug Administration to approve what would be the first-ever gene-editing treatment to hit the market using the CRISPR technolo...

Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success

Text size Intellia CEO John Leonard called the results a vindication of the company’s modular approach to Crispr therapies. Courtesy Intellia Therapeutics Patients who got a one-time gene-editin...

Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating

Crispr Therapeutics (CRSP) stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 94. As you try to find the best stocks to buy and watch, keep a close on e...

30-year-old female founder’s billion-dollar bet on CRISPR gene editing

Janice Chen (C) and her Mammoth Biosciences co-founders Trevor Martin (L) and Lucas Harrington (R). CRISPR gene editing pioneer and Nobel Prize winner Jennifer Doudna is also a co-founder. Along Highw...